In the accompanying viewpoint (page 348) Topol and Califf describe and justify one of the largest clinical trials so far attempted; in GUSTO (Global Utilisation of Streptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries) some 40 000 patients will be recruited to compare the effects of streptokinase (SK), alteplase (rt-PA), and their combination with two different heparin regimes. Although opinions may vary as to the likely outcome of GUSTO, many will agree with the song from Oklahoma, that "things have gone as far as they can go": it is hard to envisage any rationale that would lead to a further order-of-magnitude increase in trial size. Furthermore, as trials of this size are so expensive and consume so much research activity in so many centres, there must be a practical limit to the number of very big trials that can be mounted at any one time in any particular therapeutic area. GUSTO will undoubtedly provide an answer to its primary objective and be the source of much additional information; but mega-trials are not a panacea for the limitations inherent in smaller studies.
Past trials ANTICOAGULANTS The trials of indirect anticoagulants, phenindione, and warfarin, in the 1960s' 2 were based on the misconception that clotting and thrombosis were the same thing. The trials were small-not even mini-trials according to Topol and Califfs definition. The Medical Research Council trials of 1964 and 1969 contained 383 and 1427 patients. The general principle that a larger sample size will increase the likelihood that a trial will confirm the existence of a small treatment difference is now widely accepted, but the need to examine this relation quantitatively and use this to determine trial size was not at that time understood (at least by clinicans) and by today's standards the results of these trials could never be regarded as more than suggestive. Nevertheless, it was believed that anticoagulants prolonged long-term survival after myocardial infarction, particularly in younger men with repeated infarcts. The anticoagulant story might have been followed up and resolved had the attention of cardiologists not been diverted by a sudden interest in arrhythmias. An attractive possibility is that of the factorial design, in which two (or even three) treatments are compared with placebo by independent randomisation within one trial umbrella. This worked well in ISIS-2, which allowed the effect of aspirin to be studied together with streptokinase without the expense of an independent trial. However, these designs are only fully effective when there is no interaction between the two agents, and in the GISSI-2 International Study'8 it seemed that there was such an interaction between the effect ofalteplase and heparin. Multifactorial designs are, in fact, something of a gamble.
Background

META-ANALYSES
Meta-analyses of many trials, each of them on its own inadequate, is sometimes held out as a substitute for a single adequate trial. However, while meta-analyses can give an overall answer such as "antiplatelet agents reduce fatality in patients with vascular disease", or "/3 blockers reduced fatality after myocardial infarction", they can never tell a clinician which antiplatelet agent or ,B blocker, in what dose, to give to any particular patient. Meta-analysis can provide a theoretical background against which to plan further trials, but not much more.
SUB-SET ANALYSES
Sub-set analyses within individual trial results have at times been used instead of additional prospective trials to identify patients who are most likely to benefit from a particular treatment, but it is now accepted that such analyses should be used with extreme caution and are more likely to be misleading than helpful.
SURROGATE END POINTS
This leaves the surrogate end point for the poor man's clinical trial. The strategy is to identify some aspect of the patient's response that is amenable to precise measurement and is also correlated with the end point of interest. As an example, left ventricular dilatation is correlated with one month mortality after myocardial infarction. If a treatment can be shown to reduce left ventricular diltatation, then it is argued that such a treatment will also save lives. The problem is slightly different when a completely new class of drug appears for the treatment of a condition for which there is already established therapy-for example, the phosphodiesterase inhibitors for the treatment of heart failure. Under these circumstances withholding the established treatment (in the case of heart failure, an angiotensin converting enzyme inhibitor29 30) is unethical and the new therapy has to be added to the old. The chances of achieving a further large reduction in fatality by such an addition are inevitably small, and the risk that the clinical trial programme will fail to show a benefit is high. In a sense the demonstration in the PROMISE (placebo controlled survival study of oral milrinone in severe heart failure) trial that milrinone increased fatality" was useful in eliminating this drug, but suppose its effect had been neutral? Would this have implied that milrinone was of no use? After all it had clearly been shown effective in short-term intravenous studies.
The future Clearly there will always be a need for new drugs. Ideally they will be more effective, but in most cases their value will be for individual patients who fail to respond to established therapy, or who are for some reason intolerant of it. If a new drug is only to be licensed if it has been shown in a mega-trial to be superior to its predecessor, then the introduction of compounds must inevitably be inhibited. outcome for each treatment. However, in many situations the costs assigned to the various outcomes may be such that the probabilities need be known only imprecisely for equivalence to be accepted. Large trials may not be necessary.
For complete certainty about the relative effect of one drug compared with another there is no alternative to the mega-trial. Where the pharmaceutical industry sees it to be in its commercial interests the mega-trial will doubtless continue. But this may mean that minor improvements in drug development are missed because they are commercially non-viable. We may have to learn to quantify better the costs and benefits of therapies and live with a little uncertainty if we are to progress. 
